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In this study, we serologically and pathologically examined the clinical significance of
fibroblast growth factor (FGF) expression in patients with colorectal cancer. Serum basic
FGF (bFGF) levels in 92 surgical colorectal cancer patients and 31 controls were
measured, and the relationship between those levels and clinicopathological factors were
examined. Immunohistochemical study was also conducted on specimens from 51 cancer
patients, and the association between bFGF staining and serum levels were investigated.
An examination of clinicopathological factors revealed significant differences in bFGF
levels between stage 0-IIIb and stage IV cancers (P¼ 0.013). Lymphatic invasion was one
factor that differed significantly. Patients with a tumor 30 mm or smaller had a bFGF level
of 7.65 6 1.11 pg/ml while patients with a tumor 31 mm or larger had a bFGF level of 8.53
6 3.22 pg/ml; significant differences in these bFGF levels were noted (P , 0.05). Patients
with a tumor that had no lymphatic invasion (ly0) had a bFGF level of 7.25 6 0.66 pg/ml,
those with a tumor that had minimal lymphatic invasion (ly1) had a bFGF level of 7.99 6
1.68 pg/ml, and those with a tumor that had moderate lymphatic invasion (ly2) had a
bFGF level of 9.17 6 4.23 pg/ml. bFGF levels differed significantly for tumors with no/
minimal lymphatic invasion (ly0-ly1) and those with moderate lymphatic invasion (ly2)
(P, 0.0001). Serological examination of bFGF levels during the proliferation of colorectal
cancer revealed that moderate lymphatic invasion can be readily distinguished.
Among the mechanisms responsible for theprogression of cancer, cell motility is an
important factor that allows cancer cells to detach
from the primary tumor and invade nearby tissue.
Growth factors that facilitate this motility include
epidermal growth factor (EGF), transforming
growth factor b (TGF-b), and hepatocyte growth
factor (HGF). Fibroblast growth factors (FGFs) have
significant interaction with cell growth, differentia-
tion, and functioning, and they play a vital role in
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processes such as maintaining tissue and repairing
damage. Recent reports have indicated that FGFs
are involved in pathologies associated with exces-
sive cell growth and angiogenesis, such as tumor
formation. The current study examined FGF expres-
sion serologically and pathologically in patients
undergoing surgery for colorectal cancer, and this
study also examined the clinical significance of that
expression.
Subjects
Serologic investigation
There were 92 patients with colorectal cancer who
underwent surgery in the Second Department of
Surgery II at Tokyo Women’s Medical University
Hospital, from July 2000 to March 2003. There were
31 control subjects without cancer. Serum bFGF
levels of both groups were measured and compared.
The relationship between serum levels and clinico-
pathologic factors and prognosis was studied in
patients with colorectal cancer.
Patients with colorectal cancer (50 males and 42
females) had a mean age of 63.9 6 11.1 years.
Cancer was located in the colon (C-S, Rs) in 64
patients and in the rectum (Ra, Rb, P) in 28 patients.
The cancer was a well-differentiated adenocarcino-
ma in 46 patients, a moderately differentiated
adenocarcinoma in 40 patients, a poorly differenti-
ated adenocarcinoma in 6 patients, and a mucinous
carcinoma in 6 patients. The pathologic depth of
invasion was m in 5 patients, sm in 7 patients, mp in
20 patients, ss (a1) in 46 patients, se (a2) in 12
patients, and si (ai) in 2 patients. The clinical stage of
the cancer was stage 0 in 3 patients, stage I in 5
patients, stage II in 26 patients, stage IIIa in 20
patients, stage IIIb in 12 patients, and stage IV in 9
patients. The 31 patients without cancer broke down
into 16 males and 15 females with a mean age of 57.3
6 13.4 years. Ten of these patients had an inguinal
hernia, 4 patients had cholelithiasis, 1 patient had an
incisional hernia, and 1 patient had hemorrhoids.
No serious complications were noted, and blood
was collected while the patient’s condition was not
acute.
Immunohistologic investigation
Of the 92 patients with colorectal cancer, 51
underwent serologic investigation. Sections of the
innermost portion of surgical specimens were
immunohistochemically stained with anti-bFGF
antibody, and the relationship between bFGF ex-
pression and pathologic factors was examined.
Clinicopathologic findings were denoted in ac-
cordance with the Japanese Classification of Colo-
rectal Carcinoma.
Methods
Serologic investigation
Peripheral venous blood was collected preopera-
tively from patients with colorectal cancer and
patients without cancer. After centrifugation, serum
was kept frozen at 808C, and serum was thawed
before measurement. Measurement was done with
an hFGFb ELISA Kit (BioSource International,
Camarillo, CA), and serum FGF levels were mea-
sured using 1-step sandwich ELISA. Specifically, 100
lL of buffer was added to each well of an antibody
plate and 100 lL of the sample was added. Plates
were covered and allowed to stand at room
temperature for 2 hours. The reaction mixture was
then removed and plates were washed 4 times with
wash solution. Two hundred lL of FGF labeled
antibody was added to each well and plates were
covered and allowed to stand at room temperature
for 2 hours. After the reaction mixture was removed,
plates were washed 4 times with wash solution and
200 lL of chromophore solution was added to each
well. Plates were allowed to stand at room temper-
ature for 30 minutes. and then a stop solution was
added in increments of 50 lL. Absorbance was
measured with a microplate absorbance spectropho-
tometer, and antibody concentrations were deter-
mined based on a standard curve.
Immunohistologic investigation
The tissue specimens used were formalin-fixed
paraffin-embedded sections. Specimens were
stained with peroxidase (HRP)-labeled antibody
using anti-human bFGF antibody (Upstate cell
signaling solution). Specifically, 4-lm sections of
the innermost portion of the tumor were prepared.
After deparaffinization, sections were immersed in
3% H2O2 in methanol for 10 minutes. and endoge-
nous peroxidase activity was blocked. Specimens
were autoclaved at 1208C for 10 minutes and
nonspecific binding was blocked with skim milk
for 10 minutes. Specimens were then immunohisto-
chemically stained using the ABC technique. After
sections were allowed to react with diluted normal
serum at room temperature for 10 minutes, they
were allowed to react with 20-fold diluted anti-
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human bFGF antibody as the primary antibody for
60 minutes. They were then allowed to react with
biotin-labeled anti-mouse IgG antibody as the
secondary antibody for 30 minutes. They were then
allowed to react with ABC reagent for 60 minutes.
Color was developed with DAB solution. After
nuclear staining with hematoxylin, sections were
dehydrated and embedded and then examined
microscopically.
Statistical analysis
Results were subjected to a t-test. Statistical analysis
between groups was performed with a v2 test
(Fisher’s exact test), and P , 0.05 was deemed to
indicate a significant difference.
Results
Serologic investigation
Patients with colorectal cancer had a serum FGF
level of 8.16 6 2.57 pg/mL while patients without
cancer had a serum FGF level of 7.69 6 1.72 pg/mL.
Significant differences in serum FGF levels were not
noted (Fig. 1).
Statistically significant differences in terms of sex
and tumor location were not noted in patients with
colorectal cancer.
An examination of clinicopathologic factors re-
vealed no statistically significant differences in
terms of histopathologic classification, Dukes clas-
sification, venous invasion, liver metastasis, or
distant metastasis. In terms of tumor size, staging,
histologic depth of invasion, lymph node metastasis,
lymphatic invasion, and peritoneal dissemination;
however, serum bFGF levels tended to be higher as
the cancer progressed. In terms of histologic staging,
significant differences (P ¼ 0.0013) were noted
between cancers that were stages 0-IIIb and those
that were stage IV. Patients with a tumor 30 mm or
smaller had a serum bFGF level of 7.65 6 1.11 pg/
mL while patients with a tumor 31 mm or larger had
a serum bFGF level of 8.53 6 3.22 pg/mL;
significant differences (P , 0.05) in serum bFGF
levels were noted. Significant differences in terms of
the histologic depth of invasion were not noted, but
serum bFGF levels tended to be higher as cancer
penetrated further through the bowel wall. Signif-
icant differences in terms of histological lymph node
metastasis were not noted, but serum bFGF levels
tended to be higher with more extensive lymph
node metastasis. Significant differences (P , 0.0001)
were noted between minimal lymphatic invasion
(ly0 and ly1) and moderate lymphatic invasion (ly2).
Significant differences in peritoneal dissemination
were not noted, but 1 patient with peritoneal
dissemination had an extremely high level of serum
bFGF 22.53 pg/mL (Table 1).
Immunohistologic investigation
FGF staining was performed on specimens from 51
of the 92 patients whose serum FGF levels were
measured.
Patients in whom 30% or more cancer cells had a
stained cytoplasm were deemed to be FGF-positive
while patients in whom fewer than 30% of cancer
cells had a stained cytoplasm were deemed to be
FGF-negative (Fig. 2).
Of the 51 patients, 40 (78.4%) had specimens with
positive staining while 11 (21.6%) had specimens
with negative staining.
Patients who had specimens that stained positive
for FGF had a serum FGF level of 8.87 6 3.59 pg/
mL while patients who had specimens that stained
negative for FGF had a serum FGF level of 7.13 6
1.03 pg/mL. FGF levels tended to be higher in
patients who had specimens that stained positive for
FGF than those in patients who had specimens that
stained negative for FGF, but significant differences
were not noted (Fig. 3).
Discussion
FGFs are proteins that were discovered in the
pituitary of cattle that cause fibroblasts to prolifer-
FIG. 1 Serum bFGF levels between Colorectal cancer group and
Control group.
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ate.1 FGFs were subsequently found to fall into one
of 2 groups, acidic FGFs (FGF-1) and basic FGFs
(bFGF and FGF-2), because of differences in their
isoelectric point. At the present time, 22 members of
the FGF family have been identified in humans.2
bFGF is ubiquitous in the body and has strong
affinity for glycosaminoglycans like heparan sulfate.
Table 1 The relationship between clinicopathologic factors and serum
FGF levels
Mean 6 SD
(pg/mL) P value
histopathological classification
well (n ¼ 46) 7.69 6 1.57 N.S.
moderately (n ¼ 40) 8.77 6 3.41
poorly (n ¼ 6) 8.09 6 0.91
histologic stage
0 (n ¼ 3) 7.43 6 0.33 0-IIIb versus IV
P ¼ 0.013I (n ¼ 21) 7.51 6 0.95
II (n ¼ 26) 8.30 6 2.17
III a (n ¼ 20) 7.74 6 1.24
III b (n ¼ 12) 7.84 6 0.63
IV (n ¼ 9) 11.11 6 6.42
Dukes classification
A (n ¼ 25) 7.48 6 0.88 N.S.
B (n ¼ 25) 8.35 6 2.20
C (n ¼ 33) 8.22 6 2.70
D (n ¼ 9) 9.29 6 5.09
histological depth of invasion
m (n ¼ 5) 6.97 6 0.79 N.S.
sm (n ¼ 7) 7.17 6 0.61
mp (n ¼ 20) 7.97 6 1.30
ss (n ¼ 46) 8.34 6 2.60
se (n ¼ 12) 9.00 6 4.59
si (n ¼ 2) 7.36 6 0.36
lymph node metastasis
n0 (n ¼ 53) 7.87 6 1.68 n0 versus
n14 N.S.n1 (n ¼ 23) 7.85 6 1.22
n2 (n ¼ 11) 9.26 6 1.34
n3 (n ¼ 3) 7.75 6 0.41
n4 (n ¼ 2) 14.99 6 10.11
lymphatic invasion
ly0 (n ¼ 17) 7.25 6 0.66 ly0,1 versus ly2
P , 0.0001ly1 (n ¼ 51) 7.99 6 1.68
ly2 (n ¼ 24) 9.17 6 4.23
ly3 (n ¼ 0)
vascular invasion
v0 (n ¼ 63) 8.22 6 2.98 N.S.
v1 (n ¼ 26) 8.03 6 1.38
v2 (n ¼ 3) 8.00 6 0.80
v3 (n ¼ 0)
liver metastasis
H() (n ¼ 77) 8.27 6 2.77 N.S.
H(þ) (n ¼ 15) 7.56 6 0.80
peritoneal dissemination
P() (n ¼ 91) 8.00 6 2.08
P(þ) (n ¼ 1) 22.53
distant metastasis
M() (n ¼ 88) 8.18 6 2.16 N.S.
M(þ) (n ¼ 4) 7.66 6 1.24
tumor size (dia.)
30 mm þ (n ¼ 53) 7.65 6 1.11 P , 0.05
30 mm , (n ¼ 22) 8.53 6 3.22
location
C (n ¼ 4) 6.73 6 1.31 N.S.
A (n ¼18) 7.72 6 0.66
T (n ¼ 5) 8.74 6 4.04
D (n ¼ 6) 7.47 6 1.18
S (n ¼ 14) 9.10 6 4.13 FIG. 2 FGF expression in colorectal cancer, positive (A). FGF
expression in colorectal cancer, negative (B).
Table 1 Continued
Mean 6 SD
(pg/mL) P value
Rs (n ¼ 17) 8.75 6 3.66
Ra (n ¼ 11) 8.13 6 1.65
Rb (n ¼ 14) 7.76 6 0.91
P (n ¼ 3) 7.27 6 0.39
sex
male (n ¼ 50) 8.05 6 2.53 N.S
female (n ¼ 42) 8.28 6 2.63
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bFGF is stored by binding with glycosaminoglycans
present on the cell surface or in extracellular
matrix.3 When bFGF is actually needed, cells secrete
various enzymes like heparinase that free bFGF
from glycosaminoglycans so that it can reach target
cells. Levels of bFGF in the blood are extremely low,
and bFGF administered in the blood quickly
disappears. bFGF is an extremely unstable sub-
stance, and it often ceases activity while it is being
measured. Blood must be promptly centrifuged
after it is collected and serum must be collected.
Repeated freezing and thawing is unacceptable.3
FGFs are not merely fibroblast growth factors but
instead act on various cells. When they are
produced normally, FGFs are involved in cell
growth, differentiation, and functioning in processes
such as maintaining tissue and repairing damage.
FGFs are also reportedly involved in pathologies
like tumors. Cancer cells need a supply of nutrients
and oxygen via new blood vessels to grow and
develop. Angiogenesis is controlled by a balance of
promoters and inhibitors. Vascular endothelial
growth factor (VEGF) and angiopoietin (Ang) play
a key role in the balance as angiogenic growth
factors. bFGF has also received attention as yet
another angiogenic growth factor.4–6 The detailed
mechanisms of the association between FGF signal-
ing and the onset of malignant tumors remain
unclear. At the present time, however, mutations in
FGF receptors are assumed to constantly activate
FGF signaling and ultimately promote the growth
and metastasis of tumor cells.7
Patients with malignant tumors of the breast,
lungs, thyroid, colon, and kidneys have reportedly
higher serum bFGF levels than do healthy individ-
uals.812 Granato et al8 reported that patients with
breast cancer had significantly higher serum bFGF
levels, rather than serum VEGF levels, in compar-
ison to healthy individuals, and they proposed that
serum bFGF levels might serve as a tool to diagnose
breast cancer. Ueno et al9 measured serum bFGF
levels in patients with lung cancer in the form of
adenocarcinoma (AD), squamous cell carcinoma
(SQ), or small cell carcinoma (SCC). They found
that patients with AD had a serum bFGF level of 7.6
[0.5–32.5, median(range)] pg/m, those with SQ had
a serum bFGF level of 7.4 (0.5–36.7) pg/m, and those
with SC had a serum bFGF level of 7.1 (0.5–34.8) pg/
mL. These levels were significantly (P, 0.05) higher
than the serum bFGF level of 3.0 (1.5–6.0) pg/m they
noted in healthy individuals. Moreover, Ueno et al
also reported that bFGF levels in SC were associated
with prognosis. Vesely´ et al10 reported that patients
with thyroid cancer had a serum bFGF level of 5.69
6 5.58 ng/mL, and this was significantly higher (P
, 0.01) than the serum bFGF level of 1.47 6 1.77
ng/mL they noted healthy individuals. Landriscina
et al11 reported that patients with colon cancer had a
serum bFGF level of 14.3 6 12 pg/mL, which was
significantly higher (P , 0.04) than the serum bFGF
level of 6.163 pg/mL they noted healthy individ-
uals, but they also reported that serum bFGF levels
were not associated with the stage of cancer.
Takei et al13 compared serum bFGF levels before
and after surgery for breast cancer and found them
to significantly lower postoperatively compared to
the levels preoperatively. Takei et al also noted the
potential presence of bFGF secreted by tumor cells.
Landriscina et al11 studied colon cancer by measur-
ing bFGF levels in normal mucosa, in the tumor, and
in mucosa around the tumor. In contrast to Takei et
al, Landriscina et al reported lower bFGF levels in
the tumor and mucosa around the tumor than in
normal mucosa. Blood in the mesentery has high
levels of bFGF levels, and bFGF may possibly be
released at irregular intervals. Immunohistochemi-
cal evidence of bFGF has been reported in lung
cancer. Comparison of patients who tested positive
for bFGF and those who tested negative revealed
significant differences in their 5-year survival rates,
suggested an association between that bFGF is
associated with prognosis.14 The current study
examined the association between immunohistolog-
ic evidence of bFGF and serum bFGF levels in colon
cancer cells but failed to find an association between
the two. A study on the relationship to the extent of
FIG. 3 Relationship between serum FGF levels and tissue FGF
expression.
CLINICAL SIGNIFICANCE OF FGF IN COLORECTAL CANCER JIBIKI
Int Surg 2014;99 497
progression reported that a higher proportion of
patients had high bFGF levels when they had renal
cell carcinoma in a more advanced histological
stage.15 The study reported that a higher proportion
of patients had high serum bFGF levels (.30 pg/
mL) particularly when they had worse pathologic
parameters of T (tumor size) and V (vascular
invasion) and cancer with a higher grade.15 Another
study reported finding no differences in bFGF levels
in different clinical stages of non-small cell lung
cancer, but in patients with small cell cancer it found
that bFGF levels may be associated with the clinical
stage as well as the therapeutic efficacy of chemo-
therapy and radiotherapy and prognosis.9
The current study found no significant differenc-
es in the serum bFGF levels of patients with colon
cancer and patients without cancer. If, however,
patients with a serum bFGF level higher than the
mean þ 2SD of a normal individual (11.13 pg/mL)
are deemed to be patients with elevated bFGF levels
(Table 2), then 2 patients with stage IV cancer in
particular had markedly elevated bFGF. All 6
patients with elevated bFGF levels had cancer that
tested positive for lymphatic invasion.
Looking at a breakdown of the patients with
stage IV cancer indicates that 5 (mean: 7.5 6 1.12
pg/mL) had liver metastasis, 4 (mean: 7.66 6 1.24
pg/mL) had other distant metastases, 1 (22.53 pg/
mL) had peritoneal dissemination, and 2 (mean:
14.99 6 10.1 pg/mL) had n4 metastasis. Although
few patients had peritoneal dissemination or n4
metastasis, they tended to have higher serum FGF
levels.
The current study measured FGFs serologically
and it immunohistochemically stained specimens
from patients with colon cancer in order to explore
the clinical significance of FGFs. FGF levels tend to
be higher in patients with cancer that penetrated
further through the bowel wall, a larger tumor, and
more severe lymph node metastasis. Patients with
stage IV cancer and extensive lymphatic invasion in
particular had significantly higher FGF levels.
In the mouse cornea, bFGF reportedly promotes
lymphangiogenesis via signaling from VEGF recep-
tor 3 (VEGFR-3), which is expressed by lymphatic
endothelial cells. Clinically, bFGF may reportedly be
associated with lymph node metastasis in lung
carcinoma.18 The current study noted significant
differences (P , 0.0001) between minimal lymphatic
invasion (ly0 and ly1) and moderate lymphatic
invasion (ly2). This study only found 2 patients who
had lymph node metastasis (n4), but they tended to
have higher bFGF levels. These findings suggest that
bFGF is somehow involved in lymphangiogenesis.
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